使用MOST(卵巢症状与治疗关注度量表)评估卵巢癌一线化疗结束后的患者报告症状与晚期不良效应
研究纳入726例接受铂类化疗的卵巢癌患者,从诊断后6个月起每3个月完成MOST量表至多4年,描述症状患病率与轨迹。结果显示腹部、疾病或治疗相关及 wellbeing 评分在化疗结束时最差,分别于1、3、12个月改善并稳定;长期中重度疲劳32%、睡眠困难31%常见。轨迹模型显示化疗结束时MOST-DorT>30或MOST-NTx>40的患者症状持续。
要点
- 化疗结束时MOST-Abdo、MOST-DorT和MOST-Wellbeing评分最差,分别于1、3、12个月改善稳定。
- 长期中重度疲劳32%、睡眠困难31%、手脚酸痛21%、针刺感20%、焦虑18%。
- 化疗结束时MOST-DorT>30或MOST-NTx>40的患者可能症状持续,MOST可分流该高危亚组。
核心结论
- 尽管许多患者在一线化疗后3个月内报告症状改善,化疗结束时MOST-S26-DorT>30/100或MOST-S26-NTx>40/100的患者可能症状持续。
- MOST可用于分流该高危亚组以进行早期干预。
研究设计与样本
- 共726例接受铂类化疗的卵巢癌患者,从诊断后6个月开始每3个月完成MOST,持续至多4年。
- 使用描述性统计检查MOST-S26指数评分的时间变化,并使用基于组的轨迹模型识别症状持续不良的组。
主要发现
- MOST-Abdo、MOST-DorT和MOST-Wellbeing的中位评分在化疗结束时最差,分别在治疗后1、3、12个月改善并稳定。
- MOST-NTx中位评分在治疗后1个月达峰后改善,MOST-Psych中位评分随时间无实质变化。
- 长期中重度疲劳32%、睡眠困难31%、手脚酸痛21%、针刺感20%、焦虑18%常见。
- 轨迹模型显示症状持续组在治疗结束时MOST-DorT评分高于30、MOST-NTx评分高于40。
关键数值与推荐
- 化疗结束时MOST-S26-DorT>30/100或MOST-S26-NTx>40/100提示可能症状持续。
临床怎么用
- 作者认为MOST可分流化疗结束时MOST-S26-DorT>30/100或MOST-S26-NTx>40/100的高危亚组以进行早期干预。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Knowledge on the course of symptoms patients with ovarian cancer experience is limited. We documented the prevalence and trajectories of symptoms after first-line chemotherapy using the Measure of Ovarian Symptoms and Treatment concerns (MOST). METHODS: A total of 726 patients who received platinum-based chemotherapy for ovarian cancer were asked to complete the MOST every 3 months, beginning 6 months post-diagnosis and continuing for up to 4 years. We used descriptive statistics to examine temporal changes in MOST-S26 index scores for disease or treatment-related (MOST-DorT), neurotoxicity (MOST-NTx), abdominal (MOST-Abdo), and psychological (MOST-Psych) symptoms, and wellbeing (MOST-Wellbeing) and selected individual symptoms. We used group-based trajectory models to identify groups with persistently poor symptoms. RESULTS: The median MOST-Abdo, MOST-DorT and MOST-Wellbeing score were worst at chemotherapy-end but improved and stabilised by 1, 3 and 12 months after treatment, respectively. The median MOST-NTx score peaked at 1 month after treatment before improving, while the median MOST-Psych score did not change substantially over time. Long-term moderate-to-severe fatigue (32%), trouble sleeping (31%), sore hands and feet (21%), pins and needles (20%) and anxiety (18%) were common. Trajectory models revealed groups of patients with persistent symptoms had MOST-DorT scores above 30 and MOST-NTx scores above 40 at treatment-end. CONCLUSIONS: Although many patients report improvements in symptoms by 3 months after first-line chemotherapy for ovarian cancer, patients who score > 30/100 on MOST-S26-DorT or > 40/100 on MOST-S26-NTx at the end of chemotherapy are likely to have persistent symptoms. The MOST could triage this at-risk subset for early intervention.
引用
- Beesley VL, Ross TL, King MT, et al. Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecol Oncol. 2021. PMID: 34955238. doi:10.1016/j.ygyno.2021.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。